Drug Search Results
More Filters [+]

GP100:209-217

Alternative Names: gp100:209-217, gp100:209217, gp100:209 217
Latest Update: 2023-02-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GP100:209-217

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Melanoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2013-02097

P1

Completed

Melanoma

2013-09-01

NCI-2013-02096

P2

Completed

Melanoma

2013-09-01

MCC-15280

P1

Completed

Melanoma

2012-04-01

99-C-0158

P2

Completed

Melanoma

2010-05-01

Recent News Events